一例接受艾美赛珠单抗预防治疗的重型A型血友病合并COVID-19患者的血栓预防
本文报告一例接受艾美赛珠单抗预防治疗的重型A型血友病合并COVID-19患者,因COVID-19相关凝血病(CAC)潜在血栓风险,决定给予低分子肝素预防治疗,未发生血栓或出血并发症。
要点
- COVID-19可伴发CAC,基于对病毒感染的强烈炎症反应,通过不同促凝途径导致免疫血栓形成,血栓风险高。
- 新出现的证据提示,在这些患者中使用肝素可能与较低死亡率相关。
- 艾美赛珠单抗与高累积量活化凝血酶原复合物浓缩物同时使用时,曾报告血栓事件。
核心结论
- 对于接受艾美赛珠单抗预防治疗的重型A型血友病合并COVID-19患者,因CAC潜在血栓风险,给予低分子肝素预防治疗未发生血栓或出血并发症。
研究设计与样本
- 个案报告:一例接受艾美赛珠单抗预防治疗的重型A型血友病合并COVID-19患者。
主要发现
- 患者因CAC潜在血栓风险,决定给予低分子肝素预防治疗,未发生任何血栓或出血并发症。
关键数值与推荐
- 原文未报告具体低分子肝素剂量、疗程或监测阈值。
临床怎么用
- 作者报告了本病例中给予低分子肝素作为预防治疗的决定,未据此给出普遍推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 can be associated with coagulopathy (CAC, COVID-19-associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in these patients could be associated with lower mortality. Emicizumab is a bispecific humanized monoclonal antibody that bridges activated factor IX and factor X, thereby restoring the function of missing factor VIIIa in hemophilia A. The use of emicizumab has been associated with thrombotic events in patients who also received high cumulative amounts of activated prothrombin complex concentrates. Although this risk is extremely low, there is a lack of evidence on whether CAC increases the thrombotic risk in patients on emicizumab prophylaxis. We present the case of a patient with severe hemophilia A in prophylaxis treatment with emicizumab; due to the potential thrombotic risk we decided to administer low molecular weight heparin as prophylaxis treatment without any thrombotic or bleeding complications.
引用
- Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, et al. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis. J Thromb Haemost. 2020. PMID: 32526092. doi:10.1111/jth.14954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。